Compass Therapeutics (CMPX) Income from Continuing Operations (2018 - 2026)

Compass Therapeutics has disclosed Income from Continuing Operations across 9 years of filings, most recently posting 20299000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 20299000.0, down 22.04% year-over-year; the trailing twelve-month figure through Mar 2026 was 75172000.0 (down 28.45% YoY), and the FY2025 annual result was 72839000.0, down 28.63% from the prior year.
• Income from Continuing Operations came in at 20299000.0 for Q1 2026 at Compass Therapeutics, down from 17990000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 7162000.0 in Q1 2022 to a low of 21066000.0 in Q2 2025.
• The 5-year median for Income from Continuing Operations is 12239000.0 (2024), against an average of 13305882.35.
• Across the five-year window, Income from Continuing Operations sank 100.42% in 2022 and grew 16.79% in 2023, its largest moves.
• Compass Therapeutics' Income from Continuing Operations stood at 11594000.0 in 2022, then decreased by 15.71% to 13415000.0 in 2023, then declined by 23.55% to 16574000.0 in 2024, then declined by 8.54% to 17990000.0 in 2025, then declined by 12.83% to 20299000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 20299000.0 (Q1 2026), 17990000.0 (Q4 2025), and 15817000.0 (Q3 2025), per Business Quant data.